AVNeo® Newsle)er

Vol. 3 – Nov. 2022

Don’t Miss the NextWebinar!

What’s New in Research – New AVNeo® Meta-Analysis

Mark your calendars!
The next AVNeo webinar is set toair in January 2023!

Aor$c Valve Neocuspidiza$on Using the Ozaki Technique:
A Meta-analysis of Reconstructed Pa$ent-level Data

AVNeo & TAVR will be the topic ofdiscussion between Dr. Markus
Krane, Dr. Randy MarCn, and aspecial guest.

Join the AVNeo 2022 Survey!

Mylonas et al. (2022) conducted a systema3c review analyzing 1,891 pa3ents
from 22 studies (7 publica3ons on pediatric pa3ents). Mean age = 65 years in
adults and 12 years in pediatrics.

Are you interested intraining for the AVNeo®
procedure?
Training is fundamental for theAVNeo procedure. JOMDD is
supported by a network of ten(10) proctors worldwide who areresponsibleforsupporCng
cardiac surgeons through theirlearning journey.
We look forward to supporCng all
your training needs!

training@jomdd.com

Comprehensive
AVNeo®
Training Program

AVNeo oﬀers several beneﬁts:• preserves the natural expansion of the aor3c root during systole• does not require implan3ng any ﬁxed ring
• achieves maximum eﬀec3ve oriﬁce area
• results low transvalvular gradients• uses autologous pericardium• long-term an3coagula3on is not required• applicable to the full spectrum of aor3c valve pathology• ideal for small aor3c annulus• reduces risk of PPM and complex aor3c procedures
AVNeo results in excellent hemodynamic results:• indexed EOA comparable to na3ve, non-diseased aor3c valves.
• AVNeo outperformed commercially available bioprosthesis• AVNeo = 2.1 ± 0.5cm2/m2• Magana ease = 1.1-1.1cm2/m2• Freestyle (stentless bioprosthesis) = 0.9-1.0cm2/m2• Freedom from Reopera3on• Adults = 96.7% (mean f/u = 38 mo. (max = 9.8 years))• Pediatrics, = 91.3% (mean f/u = 13.9 months)• no reported cases of severe AI• late mortality <2%• endocardi3s risk = 0.5%/pa3ent year
• PPI (Permanent Pacemaker Implanta3on) = 0.7% (compared to 6%of the general AVR popula3on or 20-50% with aor3c rootenlargement)

Mylonas et al. purport that although all bioprosthesis will be prone todegenera4on, the onset of cri4cal stenosis may be delayed in AVNeo due
to physiologic EOA which is exci4ng for young ac4ve pa4ents who will
beneﬁt from low transvalvular gradients and individuals who wish toremain free of an4coagula4on (such as women of childbearing age).
Mylonas KS, Tasoudis PT, Pavlopoulos D, Kanakis M, Stavridis GT, Avgerinos DV. Aor<c valve neocuspidiza<on using the Ozaki
technique: A meta-analysis of reconstructed pa<ent-level data [published online ahead of print, 2022 Sep 14]. American HeartJournal. 2022;255:1-11. doi:10.1016/j.ahj.2022.09.003

Center of Excellence & Proctor Spotlight

Dr. Markus Krane is an adult cardiovascular surgeon and currently serves as theAssociate Professor of Surgery, the Division of Cardiac Surgery at Yale and the Directorof the AorFc Valve ReconstrucFon. Dr. Krane received his training at The German
Heart Center Munich and worked as a Consultant in Cardiac Surgery aLer he received
his board cerFﬁcaFon in 2015. Dr. Krane became the Deputy Director of theDepartment of Cardiovascular Surgery at the German Heart Center Munich in 2016
and the Head of theInsFtute for TranslaFonal
Cardiac Surgery at theGerman Heart Center
Munich in 2017.
With more than 170
procedures, he is one of
the world's mostexperienced cardiac
surgeons in performing
the AVNeo procedure forthe treatment of aorFc
valve disease, using
autologous pericardium.
JOMDD oﬀers training
courses worldwide, so
please let us know if you
need assistance.

Dr. Markus Krane
Yale University
New Haven, CT, USA

Upcoming 2022 2-Day AVNeo Training Courses
Training Dates - Loca0on - Course Director
November 21st & 22nd - Modena, Italy - Dr. Alber0ni
November 28th - Harrisburg, PA - Dr. Mumtaz
December 12th & 13th - Modena, Italy - Dr. Alber0ni
December TBD - New Haven, CT, USA –-Dr. Krane
December/January TBD– PiOsburgh, PA, USA – Dr. Chu

Contact training@jomdd.com to reserve your spot

© 2022 JOMDD Inc. All rights reserved by